Steroid-free maintenance immunosuppression in kidney transplantation: Is it time to consider it as a standard therapy

Kidney International

Volumn 76, Issue 8, 2009, Pages 825-830

  Luan, Fu L ^a,c   Steffick, Diane E ^b   Ojo, Akinlolu O ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Cardiovascular risk; Graft survival; Kidney transplant; New onset diabetes; Patient survival; Steroid free immunosuppression

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; CYCLOSPORIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG WITHDRAWAL; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MONOTHERAPY; MORBIDITY; MORTALITY; NEPHROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SHORT SURVEY;

CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; DRUG THERAPY, COMBINATION; EVIDENCE-BASED MEDICINE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PATIENT SELECTION; STEROIDS; TIME FACTORS; TREATMENT OUTCOME;

EID: 70349705641     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2009.248     Document Type: Short Survey

References (52)

1. Murray JE, Merrill JP, Harrison JH et al. Prolonged survival of humankidney homografts by immunosuppressive drug therapy. N Engl J Med 1963; 268: 1315-1323.
2. Marchioro TL, Axtell HK, Lavia MF et al. The role of adrenocortical steroids in reversing established homograft rejection. Surgery 1964; 55: 412-417.
3. Fauci AS, Dale DC. The effect of hydrocortisone on the kinetics of normal human lymphocytes. Blood 1975; 46: 235-243.
4. Almawi WY, Hadro ET, Strom TB. Evidence that glucocorticosteroidmediated immunosuppressive effects do not involve altering second messenger function. Transplantation 1991; 52: 133-140.
5. Veenstra DL, Best JH, Hornberger J et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999; 33: 829-839.
6. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006; 82: 603-611.
7. Siegel RR, Luke RG, Hellebusch AA. Reduction of toxicity of corticosteroid therapy after renal transplantation. Am J Med 1972; 53: 159-169.
8. Hricik DE, O'Toole MA, Schulak JA et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993; 4: 1300-1305.
9. Schulak JA, Mayes JT, Moritz CE et al. A prospective randomized trial of prednisone versus no prednisone maintenance therapy in cyclosporinetreated and azathioprine-treated renal transplant patients. Transplantation 1990; 49: 327-332.
10. Griffin PJ, Da Costa CA, Salaman JR. A controlled trial of steroids in cyclosporine-treated renal transplant recipients. Transplantation 1987; 43: 505-508.
11. Sinclair NR. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992; 147: 645-657.
12. Kasiske BL, Chakkera HA, Louis TA et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910-1917.
13. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995; 60: 225-232.
14. A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1996; 61: 1029-1037.
15. Brennan DC, Flavin K, Lowell JA et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011-1018.
16. Nashan B, Moore R, Amlot P et al. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group. Lancet 1997; 350: 1193-1198.
17. Luan FL, Steffick DE, Gadegbeku C et al. Graft and patient survival in kidney transplant recipients selected for de novo steroid-free maintenance immunosuppression. Am J Transplant 2009; 9: 160-168.
18. Ahsan N, Hricik D, Matas A et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Steroid Withdrawal Study Group. Transplantation 1999; 68: 1865-1874.
19. Vanrenterghem Y, Lebranchu Y, Hene R et al. Double-blind comparison of two corticosteroid regimens plus mycophenolate mofetil and cyclosporine for prevention of acute renal allograft rejection. Transplantation 2000; 70: 1352-1359.
20. Almawi WY, Hess DA, Assi JW et al. Pretreatment with glucocorticoids enhances T-cell effector function: possible implication for immune rebound accompanying glucocorticoid withdrawal. Cell Transplant 1999; 8: 637-647.
21. Matas AJ, Ramcharan T, Paraskevas S et al. Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant 2001; 1: 278-283.
22. Vincenti F, Monaco A, Grinyo J et al. Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporine microemulsion and mycophenolate mofetil. Am J Transplant 2003; 3: 306-311.
23. Vincenti F, Schena FP, Paraskevas S et al. A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients. Am J Transplant 2008; 8: 307-316.
24. Rajab A, Pelletier RP, Henry ML et al. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression. Clin Transplant 2006; 20: 537-546.
25. Shapiro R, Jordan ML, Scantlebury VP et al. Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. Transplant Proc 1998; 30: 1375-1377.
26. Vincenti F, Jensik SC, Filo RS et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782.
27. Gonwa T, Johnson C, Ahsan N et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75: 2048-2053.
28. Squifflet JP, Vanrenterghem Y, van Hooff JP et al. Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 2002; 34: 1584-1586.
29. Rostaing L, Cantarovich D, Mourad G et al. Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation. Transplantation 2005; 79: 807-814.
30. Matas AJ, Kandaswamy R, Humar A et al. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg 2004; 240: 510-516; discussion 516-517.
31. Matas AJ, Kandaswamy R, Gillingham KJ et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005; 5: 2473-2478.
32. Anil Kumar MS, Heifets M, Fyfe B et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005; 80: 807-814.
33. Kumar MS, Heifets M, Moritz MJ et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation 2006; 81: 832-839.
34. Hricik DE, Whalen CC, Lautman J et al. Withdrawal of steroids after renal transplantation-clinical predictors of outcome. Transplantation 1992; 53: 41-45.
35. Hricik DE, Knauss TC, Bodziak KA et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003; 76: 938-942.
36. Gruber SA, West MS, Sillix DH et al. Preliminary results with early corticosteroid withdrawal in African American renal allograft recipients. Surgery 2005; 138: 772-778; discussion 778-779.
37. Woodle ES, First MR, Pirsch J et al. A prospective, randomized, doubleblind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577.
38. Tan HP, Donaldson J, Basu A et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. Am J Transplant 2009; 9: 355-366.
39. Boots JM, Christiaans MH, Van Duijnhoven EM et al. Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. Transplantation 2002; 74: 1703-1709.
40. Woodle ES, Alloway RR, Buell JF et al. Multivariate analysis of risk factors for acute rejection in early corticosteroid cessation regimens under modern immunosuppression. Am J Transplant 2005; 5: 2740-2744.
41. Humar A, Gillingham K, Kandaswamy R et al. Steroid avoidance regimens: a comparison of outcomes with maintenance steroids versus continued steroid avoidance in recipients having an acute rejection episode. Am J Transplant 2007; 7: 1948-1953.
42. Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol 2000; 11: 1735-1743.
43. Smak Gregoor PJ, de Sevaux RG, Ligtenberg G et al. Withdrawal of cyclosporine or prednisone six months after kidney transplantation in patients on triple drug therapy: a randomized, prospective, multicenter study. J Am Soc Nephrol 2002; 13: 1365-1373.
44. Kasiske BL, Snyder JJ, Gilbertson D et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
45. Hjelmesaeth J, Hartmann A, Leivestad T et al. The impact of earlydiagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int 2006; 69: 588-595.
46. Cosio FG, Kudva Y, van der Velde M et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415-2421.
47. Ruiz JO, Simmons RL, Callender CO et al. Steroid diabetes in renal transplant recipients: pathogenetic factors and prognosis. Surgery 1973; 73: 759-765.
48. Friedman EA, Shyh TP, Beyer MM et al. Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 1985; 5: 196-202.
49. Arner P, Gunnarsson R, Blomdahl S et al. Some characteristics of steroid diabetes: a study in renal-transplant recipients receiving high-dose corticosteroid therapy. Diabetes Care 1983; 6: 23-25.
50. Arnol M, de Mattos AM, Chung JS et al. Late steroid withdrawal and cardiovascular events in kidney transplant recipients. Transplantation 2008; 86: 1844-1848.
51. Rike AH, Mogilishetty G, Alloway RR et al. Cardiovascular risk, cardiovascular events, and metabolic syndrome in renal transplantation: comparison of early steroid withdrawal and chronic steroids. Clin Transplant 2008; 22: 229-235.
52. -2007 Annual Report of US Procurement Network, the Scientific Registry of Transplant Recipients, Transplant Data 1994-2006. 2008. In: Department of Health and Human Service, Human Resource and Service Administration, Healthcare System Bureau, Division of Transplantation, et al. (eds). Rockville, Richmond, Ann Arbor. Annual Report Online at http://www.ustransplant.org/annual-reports/ current/ last accessed March 2009.